Kailera Therapeutics (NASDAQ:KLRA) Stock Price Up 6.6% – Here’s Why

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s stock price was up 6.6% during trading on Monday . The company traded as high as $19.21 and last traded at $19.13. 341,212 shares were traded during trading, a decline of 51% from the average session volume of 700,079 shares. The stock had previously closed at $17.94.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on KLRA shares. Evercore initiated coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “outperform” rating for the company. TD Cowen assumed coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set a “buy” rating and a $57.00 price target on the stock. Wall Street Zen lowered shares of Kailera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a research report on Wednesday, May 13th. Finally, William Blair began coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $42.75.

Kailera Therapeutics Stock Performance

The business’s fifty day moving average price is $19.43. The stock has a market cap of $2.48 billion and a price-to-earnings ratio of -0.01.

Kailera Therapeutics (NASDAQ:KLRA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.35). On average, equities analysts predict that Kailera Therapeutics, Inc. will post -3.63 EPS for the current fiscal year.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.